Open Label Extension Study to Evaluate the Safety, Tolerability and Cognitive Effects of VEL015 (Sodium Selenate) in Patients with Alzheimer's Disease

Trial Profile

Open Label Extension Study to Evaluate the Safety, Tolerability and Cognitive Effects of VEL015 (Sodium Selenate) in Patients with Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Sodium selenate (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 19 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top